Cancer immunotherapy via stem cell-derived NK cells.

NK cells are the first sentinels of the immune system that can recognize and eradicate transformed cells. Their activation without a need for additional signaling have attracted great attention on the use of NK cells as a promising option in cancer immunotherapy. However, the large-scale production of NK cells for successful NK cells therapy is a challenge that needs to be tackled. Engineering NK cells to avoid tumor escape and improve their antitumor potency are the other matters of focus that have widely been studied in the recent years. This paper reviews the most recent advances in the stem cell-derived NK cell technology and discusses the potential of the engineered NK cells for clinical applications in cancer immunotherapy.

• Publication year

  2023

• Venue

  Immunotherapy

• Publication date

  2023-06-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/imt-2022-0224PMID 37337708
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy

  2022cited by this paper
• Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells

  2022cited by this paper
• Generation of universal natural killer cells from a cryopreserved cord blood mononuclear cell‐derived induced pluripotent stem cell library

  2022cited by this paper
• Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer

  2022cited by this paper
• Roles of natural killer cells in immunity to cancer, and applications to immunotherapy

  2022cited by this paper
• Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy

  2022cited by this paper
• iPSC-Derived Natural Killer Cells for Cancer Immunotherapy

  2021cited by this paper
• Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors

  2021cited by this paper
• An Alternative Cell Therapy for Cancers: Induced Pluripotent Stem Cell (iPSC)-Derived Natural Killer Cells

  2021cited by this paper
• Engineering the next generation of CAR-NK immunotherapies

  2021cited by this paper
• Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy

  2021cited by this paper
• Natural killer cells: of-the-shelf cytotherapy for cancer immunosurveillance.

  2021cited by this paper
• Engineering Metabolism of Chimeric Antigen Receptor (CAR) Cells for Developing Efficient Immunotherapies

  2021cited by this paper
• SnapShot: Natural Killer Cells.

  2020cited by this paper
• Directed Differentiation of Mobilized Hematopoietic Stem and Progenitor Cells into Functional NK Cells with Enhanced Antitumor Activity

  2020cited by this paper
• Natural killer cells in cancer biology and therapy

  2020cited by this paper
• NK cells for cancer immunotherapy

  2020cited by this paper
• NK Cell-Based Immunotherapies in Cancer

  2020cited by this paper
• Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies

  2020cited by this paper
• Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.

  2019cited by this paper
• Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy

  2019cited by this paper
• 3D model for CAR‐mediated cytotoxicity using patient‐derived colorectal cancer organoids

  2019cited by this paper
• CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma

  2019cited by this paper
• NK Cell-Based Immunotherapy for Hematological Malignancies

  2019cited by this paper
• Adoptive cell therapy using engineered natural killer cells

  2019cited by this paper
• The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their ex vivo Expansion and Cytotoxic Potential Against Neuroblastoma: Perspective for Optimized Immunotherapy Post Haploidentical Stem Cell Transplantation

  2019cited by this paper
• 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies

  2019cited by this paper
• Complete response of metastatic melanoma in a patient with Crohn’s disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies

  2019cited by this paper
• Current challenges and emerging opportunities of CAR-T cell therapies.

  2019cited by this paper
• Could iPSCs Enable "Off-the-Shelf" Cell Therapy?

  2019cited by this paper
• Engineered human pluripotent stem cell-derived natural killer cells: the next frontier for cancer immunotherapy

  2019cited by this paper
• Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy

  2019cited by this paper
• Chimeric antigen receptor (CAR)-modified NK cells against cancer: Opportunities and challenges.

  2019cited by this paper
• Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells

  2018cited by this paper
• Application of small molecule CHIR99021 leads to the loss of hemangioblast progenitor and increased hematopoiesis of human pluripotent stem cells.

  2018cited by this paper
• In Vivo Study of Natural Killer (NK) Cell Cytotoxicity Against Cholangiocarcinoma in a Nude Mouse Model

  2018cited by this paper
• Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity.

  2018cited by this paper
• Natural killer cells and other innate lymphoid cells in cancer

  2018cited by this paper
• Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

  2018cited by this paper
• Tumor Microenvironment-Induced Immunometabolic Reprogramming of Natural Killer Cells

  2018cited by this paper
• Cytokines in clinical cancer immunotherapy

  2018cited by this paper
• Concise Review: Human Pluripotent Stem Cells to Produce Cell‐Based Cancer Immunotherapy

  2018cited by this paper
• Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity

  2018cited by this paper
• CAR T cell immunotherapy for human cancer

  2018cited by this paper
• The Principles of Engineering Immune Cells to Treat Cancer.

  2017cited by this paper
• Engineering Natural Killer Cells for Cancer Immunotherapy.

  2017cited by this paper
• Umbilical Cord Blood Natural Killer Cells, Their Characteristics, and Potential Clinical Applications

  2017cited by this paper
• Type I Interferons and Natural Killer Cell Regulation in Cancer

  2017cited by this paper
• A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy

  2017cited by this paper
• Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity

  2017cited by this paper
• Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients

  2017cited by this paper
• Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts

  2017cited by this paper
• Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies

  2017cited by this paper
• Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells

  2016cited by this paper
• Large-Scale Culture and Genetic Modification of Human Natural Killer Cells for Cellular Therapy.

  2016cited by this paper
• Targeting natural killer cells in cancer immunotherapy

  2016cited by this paper
• A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer

  2016cited by this paper
• Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: On being in the right place at the right time, with resilience

  2016cited by this paper
• Induced Pluripotent Stem Cell‐Derived Natural Killer Cells for Treatment of Ovarian Cancer

  2016cited by this paper
• IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells

  2016cited by this paper
• Exploitation of natural killer cells for the treatment of acute leukemia.

  2016cited by this paper
• CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes

  2016cited by this paper
• Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells.

  2016cited by this paper
• Challenges and opportunities of allogeneic donor-derived CAR T cells

  2015cited by this paper
• CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells

  2015cited by this paper
• Multiple effects of IL-21 on human NK cells in ex vivo expansion.

  2015cited by this paper
• How Do Cytotoxic Lymphocytes Kill Cancer Cells?

  2015cited by this paper
• Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity

  2015cited by this paper
• Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.

  2015cited by this paper
• NK cells and cancer: you can teach innate cells new tricks

  2015cited by this paper
• Effect of tumor cells and tumor microenvironment on NK‐cell function

  2014cited by this paper
• Expression of Chimeric Receptor CD4ζ by Natural Killer Cells Derived from Human Pluripotent Stem Cells Improves In Vitro Activity but Does Not Enhance Suppression of HIV Infection In Vivo

  2014cited by this paper
• The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential

  2013cited by this paper
• Clinical‐Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy

  2013cited by this paper
• Controlling natural killer cell responses: integration of signals for activation and inhibition.

  2013cited by this paper
• Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors

  2013cited by this paper
• A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells.

  2013cited by this paper
• New insights into the role of NK cells in cancer immunotherapy

  2012cited by this paper
• Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells

  2012cited by this paper
• Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus?

  2012cited by this paper
• A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies.

  2012cited by this paper
• Decreased expression of DNAM‐1 on NK cells from acute myeloid leukemia patients

  2012cited by this paper
• A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.

  2011cited by this paper
• Potential Clinical Applications for Human Pluripotent Stem Cell-Derived Blood Components

  2011cited by this paper
• Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients.

  2010cited by this paper
• NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.

  2010cited by this paper
• Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity.

  2009cited by this paper
• Graft-versus-host disease.

  2009cited by this paper
• Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction.

  2007cited by this paper
• CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner

  2005cited by this paper
• Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.

  2005cited by this paper
• Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.

  2005cited by this paper
• Inhibition of indoleamine 2,3-dioxygenase suppresses NK cell activity and accelerates tumor growth.

  2003cited by this paper
• Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants

  2002cited by this paper
• Role of TNF Family Ligands in Antitumor Activity of Natural Killer Cells

  2001cited by this paper
• Regulation of the natural killer cell receptor repertoire.

  2001cited by this paper
• A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood.

  1996cited by this paper
• Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor

  1994cited by this paper
• In search of the 'missing self': MHC molecules and NK cell recognition.

  1990cited by this paper
• Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.

  1981cited by this paper

• Enhancing NK Cell Antitumor Activity With Natural Compounds: Research Advances and Molecular Mechanisms

  2025cites this paper
• Nanomaterial assisted natural killer cell therapy

  2025cites this paper
• Cytokine-Treated Natural Killer Cells Derived from Cord Blood Haematopoietic Stem Cells Exhibit Potential Cytotoxicity Against Cancer Cells

  2024cites this paper